secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-063987
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences Q1 net loss $72M; cash $245.7M; SUMMIT readout in July
-------------------------------------------------------------------------

- Net loss $72.0M vs $58.3M YoY; R&D spend $63.0M (+20% YoY) driven by ongoing trials.
- Cash & securities $245.7M, funded into late 2026; raised $24.3M via ATM in Q1.
- Top-line SUMMIT results in non-AdvSM due July 2025; APEX AdvSM in H2, PEAK GIST by year-end.
- Bezuclastinib OLE data showed 65% mean TSS improvement at 48 weeks; 88% achieved ≥50% reduction.
- Early-stage pipeline (KRAS, PI3Kα, FGFR2/3, ErbB2) preclinical data presented at AACR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017025063987/0000950170-25-063987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017025063987/cogt-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer